drugset / Trial / NCT07546981

Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists

NCT07546981

Phase 3 Recruiting 554 enrolled Chiesi Farmaceutici S.p.A.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a study comparing CHF 5993 pMDI HFA-152a with CHF 1535 pMDI HFA-134a in Chinese patients with asthma uncontrolled on medium doses of ICS+LABA.

Timeline

Start
2026-06-26
Primary completion
2028-10-17
Completion
2028-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject CHF 5993 Other / unclassified Inhaled
Subject CHF1535 Unknown Inhaled

Indications